NewsBenzingaReported Sunday, Abbott’s TECTONIC Trial Of Investigational SonicForce Coronary IVL System Meets Primary Safety And Effectiveness Endpoints, With 0.3% 30-Day Target Lesion Failure And 97% Procedural Success In 335 Patient Reported Sunday, Abbott’s TECTONIC Trial Of Investigational SonicForce Coronary IVL System Meets Primary Safety And Effectiveness Endpoints, With 0.3% 30-Day Target Lesion Failure And 97% Procedural Success In 335 Patient Benzinga 2026.11.02 06:39 (GMT+0) Open on Benzinga Other news Keefe, Bruyette & Woods Upgrades PennyMac Mortgage IT to Outperform, Lowers Price Target to $10 Bill Ackman Says Elon Musk May Need $1 Trillion for SPCX AI Buildout: ‘Competing at Sovereign Levels’ 3 Token Unlocks to Watch in the First Week of November 2026 Nasdaq Tumbles Over 700 Points as Chip Stocks Fall: Investor Sentiment Weakens, Greed Index Remains in ‘Fear’ Zone Apple, Marriott International and 3 Stocks to Watch Heading Into Monday Morgan Stanley: Global Data Center Capacity May Reach 316GW by 2030
Bill Ackman Says Elon Musk May Need $1 Trillion for SPCX AI Buildout: ‘Competing at Sovereign Levels’
Nasdaq Tumbles Over 700 Points as Chip Stocks Fall: Investor Sentiment Weakens, Greed Index Remains in ‘Fear’ Zone
